Previous 10 | Next 10 |
2023-09-20 08:53:10 ET More on Regulus Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics For further details see: Regulus posts early Phase 1 data f...
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Statistically significant incre...
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Sept. 13, 202...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovati...
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 PR Newswire SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative me...
2023-08-08 17:29:56 ET Regulus Therapeutics press release ( NASDAQ: RGLS ): Q2 GAAP EPS of -$0.37 beats by $0.04 . As of June 30, 2023, Regulus had $37.3 million in cash and cash equivalents. The Company expects its cash runway to extend into mid-2024. For furthe...
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates PR Newswire First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 ...
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire SAN DIEGO , Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of ...
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference PR Newswire SAN DIEGO , July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of in...
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , June 27, 2023 /PRNewswire/ -...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disea...
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. ...